Introduction
============

Chronic obstructive pulmonary disease (COPD) is currently the fourth leading cause of death; the prevalence of COPD is rapidly increasing, and it is expected to be the third most fatal disease in the world by 2030.[@b1-copd-13-2695] This disease affects approximately 65 million people in the world, of which 90% deaths occurred in low- and middle-income countries.[@b2-copd-13-2695] COPD is a disease state characterized by progressive and partially reversible airflow obstruction. It is usually accompanied by mucus hypersecretion, inflammation, and oxidation stress in airway and lung.[@b3-copd-13-2695] Later, it can induce symptoms such as dyspnea, nutritional depletion, and diseases such as pulmonary heart disease, diabetes, and depression, all of which cause great impact on the quality of life and health of patients.[@b4-copd-13-2695],[@b5-copd-13-2695] Since COPD results in great financial and health burdens, it is important to make early, appropriate diagnosis and take steps for the treatment of COPD.

Fractional exhaled nitric oxide (FENO), a biomarker synthesized endogenously in the human respiratory tract, plays a key role in physiological regulation of airway function, including neurotransmission, vasodilation, and immunoregulation.[@b6-copd-13-2695] Moreover, FENO is implicated in the pathophysiology of airway disease, and elevated FENO level is found in inflammatory lung disorders such as asthma, pulmonary hypertension, and cystic fibrosis.[@b7-copd-13-2695] The measurement of FENO has been suggested as a simple and noninvasive test in eosinophilic airway inflammation, and the utility in aiding diagnosis and monitoring of asthma has also been confirmed.[@b7-copd-13-2695],[@b8-copd-13-2695] However, limited by the inconsistent results of FENO level in COPD, the value and application in this case still remains unknown. Interestingly, it was reported that FENO levels in patients with COPD could be reduced by smoking and inhaled corticosteroids, which indicated they were confounding factors in measuring FENO levels in COPD. COPD involves excessive inflammation in airway and lung, which induces the release of numerous proinflammatory cytokines. Yet, the available studies regarding FENO levels are controversial and conflicting in their conclusions. To address this issue, we performed a systematic review and meta-analysis of published studies to determine the levels of FENO in COPD, aiming to further the understanding of the role of FENO in patients with COPD.

Methods
=======

Search strategy
---------------

A systematic search of PubMed, Embase, and Cochrane Library was conducted up to January 2018. We searched for the terms ("chronic obstructive pulmonary disease" or "COPD") and ("fractional exhaled nitric oxide" or "exhaled nitric oxide" or "nitric oxide" or "FENO"). The search was limited to articles published in the English language and conducted in humans. To ensure that all relevant studies were included, we screened bibliographies of relevant review articles and searched the clinical trial registry ([www.ClinicalTrials.gov](http://www.ClinicalTrials.gov)) for additional studies. Case reports, reviews, editorials, comments, practice guidelines, historical articles, and news were excluded.

Study selection
---------------

Two reviewers (ZL and CC) screened titles and abstracts independently to identify potential relevant citations. Then, the full texts were retrieved and reviewed to confirm eligibility. Differences between the reviewers were resolved by discussion and, if necessary, in consultation with a senior investigator (QD). Studies were included if they met the following criteria: 1) Studies reported FENO levels in both patient group and control group quantitatively. 2) FENO levels were expressed as mean ± standard deviation, median and range, or median and interquartile range. 3) Patients with COPD and controls had no history of asthma or other respiratory disease.

Data extraction and quality assessment
--------------------------------------

The extracted information included study source (surname of first author and year of publication), study design, study population, gender, sample size, diagnostic standard of COPD, FENO measurement, and FENO levels (in parts per billion or ppb) in patients with COPD and in controls. We derived FENO levels expressed as mean ± standard deviation preferentially. If not available, the median and range, or median and interquartile range were extracted. If multiple flow rates were applied in FENO, we then derived the data at 50 mL/s flow rate. Quality assessment of cross-sectional studies was conducted by using an 11-item checklist recommended by Agency for Healthcare Research and Quality. Article quality was assessed as follows: low quality ranged from 0 to 3, moderate quality ranged from 4 to 7, and high quality ranged from 8 to 11. As for case--control studies, we applied the Newcastle--Ottawa Quality Assessment Scale, with a total score of 0--3, 4--6, and 7--9 considered low, moderate, and high quality, respectively. The quality of all studies was evaluated by a consensus meeting with all authors. Low-quality studies were excluded from our meta-analysis.

Data analysis
-------------

The means and standard deviation were pooled and calculated between patients with COPD and controls. For studies reporting median and range, or median and interquartile range, we analyzed means and standard deviation based on the method proposed by Hozo et al.[@b9-copd-13-2695] For studies reporting FENO levels in stable and exacerbated COPD, both levels were calculated. If there were 2 or more control groups in the included studies, we chose the best match for each group (ex-smokers group and current smokers group). Furthermore, we performed subgroup analyses regarding COPD status including stable and exacerbated COPD, as well as smoking status (ex-smokers and current smokers) in patients with COPD. According to the included studies, stable status was free from no exacerbation of symptom (increased breathlessness, increased cough, and increased sputum production) before research. Exacerbated COPD was defined as acute exacerbation, with a symptom of increased breathlessness, increased cough, and increased sputum production. Heterogeneity was assessed by the *I*^2^ statistics, with a value of 25%--49% representing low heterogeneity, 50%--75% moderate heterogeneity, and \>75% high heterogeneity. Considering the high heterogeneity, a random-effects model was applied to combine the overall effect. In addition, 2 reviewers (ZL and CC) independently used the funnel plot to check the publication bias, and Egger's test was done to access the asymmetry of funnel plots. A 2-sided *P*-value \<0.05 was judged to indicate statistical significance. Differences between the reviewers were resolved by discussion and, if necessary, in consultation with a senior investigator (QD). We also performed a sensitivity analysis to explore the stability of the meta-analysis. All statistical analyses were conducted with Review Manager version 5.3 (The Cochrane Collaboration, London, UK) and Stata version 13 (StataCorp LLC, College Station, TX, USA).

Results
=======

Study selection
---------------

[Figure 1](#f1-copd-13-2695){ref-type="fig"} shows details of literature and study selection. Initially, we identified 2,073 records in the electronic databases. After removing duplicates, 1,466 records were left for title and abstract screening. Then, 1,426 citations were discarded, as they were not related to the topic. The remaining 40 studies were retrieved for full-text evaluation. No available data was provided in 4 studies. Nine studies were not related to our study. Two studies reported that patients with COPD had other respiratory disease, and 1 study reported that participants in the control group had respiratory disease. Eventually, 24 studies were included in this systematic review and meta-analysis, with 22 cross-sectional studies[@b10-copd-13-2695]--[@b31-copd-13-2695] and 2 case--control studies.[@b32-copd-13-2695],[@b33-copd-13-2695] As for quality assessment, all the cross-sectional studies had a relatively moderate quality while the case--control studies (Agency for Healthcare Research and Quality score ranged from 4 to 7) had a relatively high quality (Newcastle--Ottawa Quality Assessment Scale score \>7).

Detailed characteristics of included studies are provided in [Table 1](#t1-copd-13-2695){ref-type="table"}. The sample size across studies varied from 21 to 212, with a total number of 1,669. The majority of studies were from Europe,[@b10-copd-13-2695]--[@b12-copd-13-2695],[@b15-copd-13-2695],[@b18-copd-13-2695]--[@b20-copd-13-2695],[@b22-copd-13-2695],[@b23-copd-13-2695],[@b26-copd-13-2695]--[@b30-copd-13-2695],[@b33-copd-13-2695] with 1 study from Australia,[@b17-copd-13-2695] 1 study from America,[@b13-copd-13-2695] 2 studies from Africa,[@b21-copd-13-2695],[@b32-copd-13-2695] and 5 studies from Asia.[@b14-copd-13-2695],[@b16-copd-13-2695],[@b24-copd-13-2695],[@b25-copd-13-2695],[@b31-copd-13-2695] In terms of diagnosis of COPD, 9 studies used doctor-diagnosis,[@b13-copd-13-2695],[@b15-copd-13-2695],[@b17-copd-13-2695],[@b21-copd-13-2695],[@b23-copd-13-2695],[@b29-copd-13-2695],[@b31-copd-13-2695],[@b32-copd-13-2695] 8 studies used GOLD guideline,[@b10-copd-13-2695],[@b12-copd-13-2695],[@b14-copd-13-2695],[@b18-copd-13-2695],[@b22-copd-13-2695],[@b24-copd-13-2695],[@b26-copd-13-2695],[@b30-copd-13-2695],[@b33-copd-13-2695] 2 applied American Thoracic Society criteria,[@b11-copd-13-2695],[@b16-copd-13-2695] 2 applied European Respiratory Society criteria,[@b20-copd-13-2695],[@b27-copd-13-2695] 2 applied British Thoracic Society guidelines,[@b19-copd-13-2695],[@b28-copd-13-2695] and 1 applied Chinese Medical Association guidelines.[@b25-copd-13-2695]

FENO in patients with COPD
--------------------------

A total of 24 studies evaluated FENO levels in patients with COPD and controls. Due to the evidence of great heterogeneity (*I*^2^=96%), a random-effect model was used in this meta-analysis. The pooled standard mean difference (SMD) was 1.28 (95% confidence interval \[CI\] 0.60--1.96), which indicated FENO levels were slightly elevated in patients with COPD compared with controls ([Figure 2](#f2-copd-13-2695){ref-type="fig"} and [Table 2](#t2-copd-13-2695){ref-type="table"}).

Subgroup analyses
-----------------

Based on COPD status (stable or exacerbated), we conducted subgroup analyses to evaluate the association between COPD status and FENO levels. Twenty studies were included in the subgroup of stable COPD, contributing 1,393 participants for this meta-analysis. The calculated SMD was 1.21 (95% CI 0.47--1.96), which meant FENO levels were 1.21 (95% CI 0.47--1.96) higher than those in the control group ([Figure 3](#f3-copd-13-2695){ref-type="fig"} and [Table 2](#t2-copd-13-2695){ref-type="table"}). As for subgroup of exacerbated COPD, 2 studies were enrolled and 53 participants were included. The calculated SMD (3.20, 95% CI −3.22 to 9.61) indicated that there was no association between exacerbated COPD and FENO levels in our meta-analysis ([Figure 3](#f3-copd-13-2695){ref-type="fig"} and [Table 2](#t2-copd-13-2695){ref-type="table"}).

Considering the smoking status in patients with COPD, we performed another subgroup analysis to compare FENO levels between ex-smokers and current smokers in COPD. A random-effect model was used because of the high heterogeneity (*I*^2^=90%). The result revealed that FENO levels in ex-smokers were higher than those in current smokers, with a pooled SMD of 2.05 (95% CI 1.13--2.97) ([Figure 4](#f4-copd-13-2695){ref-type="fig"} and [Table 2](#t2-copd-13-2695){ref-type="table"}).

Sensitivity analysis and publication bias
-----------------------------------------

We sequentially extracted each study and performed a sensitivity analysis. We found that the SMDs were not materially altered, which showed the stability of this meta-analysis ([Figure S1](#SD1-copd-13-2695){ref-type="supplementary-material"}). The funnel plot demonstrated asymmetry, indicating an obvious bias. Further ([Figure S2](#SD2-copd-13-2695){ref-type="supplementary-material"}), the Egger's tests also suggested the presence of publication bias among the included studies (*P*\<0.001).

Discussion
==========

To our knowledge, this is the first meta-analysis assessing FENO levels in patients with COPD. Twenty-four studies and 1,393 participants were included in the systematic review and meta-analysis. The results showed elevated FENO levels in patients with COPD compared with healthy controls. Further, the subgroup analyses, which were based on the disease state of COPD, revealed that patients with stable COPD had a mild elevation of FENO levels. No association was found between FENO levels and exacerbated COPD, which might result from the limited number of studies. And for subjects with COPD, it was found that FENO levels were much higher in ex-smokers than those in current smokers.

Identifying biomarkers for COPD could reflect disease state and underlying pathology. FENO has been a marker for eosinophilic inflammation. Positive correlation between FENO and eosinophilia has been confirmed in induced sputum and bronchoalveolar lavage.[@b34-copd-13-2695],[@b35-copd-13-2695] Since asthma is a disease characterized by airway inflammation via eosinophilic cellular pathway, FENO measurement has value in aiding in the diagnosis of asthma. However, its role in COPD still remains controversial because of a different type of airway inflammation.

COPD is mainly characterized by overexpression and infiltration of neutrophils, macrophages, and T-lymphocytes.[@b36-copd-13-2695] Numerous inflammatory cytokines are then produced and released; such process might include synthesis of iNOS by macrophages, epithelium, and vascular smooth muscle in airway.[@b37-copd-13-2695] In response to stimulants such as viral infections, elevated NO level inversely reflects on the inflammatory process by production of proinflammatory cytokines in the airway and pulmonary system.[@b38-copd-13-2695] On the other hand, evidence showed bacterial infections decreased FENO levels.[@b39-copd-13-2695] Interestingly, the high concentration of NO in cigarette smoke was believed to reduce FENO, which might result from changes in NO mechanism. It was reported the high concentration of NO produced by cigarette smoking downregulated NOS. Besides, another possibly was that oxidants in smoke directly caused damage to bronchial epithelial cells and suppressed production of NO.[@b40-copd-13-2695],[@b41-copd-13-2695] Since the precise mechanism is not fully understood, we need more research in this field. Agusti et al[@b29-copd-13-2695] found an obvious elevation of FENO levels in exacerbated COPD, and the potential mechanism might be associated with a burst of eosinophilic inflammation and activation of NOS. Pedoto et al[@b42-copd-13-2695] suggested another mechanism: acidosis, which occurred in COPD exacerbation. This acted on the vasculature and resulted in activated myeloperoxidase activity, and eventually increased FENO levels. These findings indicated FENO is a surrogate biomarker and method to detect disease activity in COPD. However, we could not conclude an elevation in exacerbated COPD due to the reduced number of studies included here.

FENO might be a biomarker for corticosteroid treatment. Lim et al[@b43-copd-13-2695] conducted a meta-analysis and concluded that inhaled corticosteroids decreased FENO levels in patients with COPD, especially in ex-smokers with COPD. However, limited by the data, it was not clear whether such changes existed in current smokers with COPD. The observation indicated that airway inflammation in COPD was corticosteroid sensitive, which meant corticosteroids might reflect on NO mechanism, NOS, and NO-producing epithelial cells. Yet, the underlying mechanism remains unknown and requires further research. Interestingly, regardless of use of inhaled corticosteroids, FENO remained at a high concentration during hospitalization and returned to normal values only after several months of inhaled corticosteroids therapy.[@b29-copd-13-2695] This was different from the effect of inhaled corticosteroids in asthma, but consistent with result observed in stable COPD.[@b44-copd-13-2695] Such a difference has also been reported in induced sputum.[@b45-copd-13-2695] Thus, these results supported the concept that the potential inflammatory pathology between asthma and COPD is not the same. In addition, there were some factors increasing FENO levels including nitrate-rich diets and viral infections, as well as factors decreasing FENO levels such as exercise and bronchoconstriction.[@b6-copd-13-2695]

Limitations
===========

Several limitations of our meta-analysis need to be emphasized. First is the relatively small number of participants included. The total number was still not large enough, which may lower the statistical significance. Second, inconsistent measurements of FENO were used. Multiple analyzers and expiratory flow rates were applied, which might be reasons why FENO levels varied widely among the studies. The validity of a meta-analysis mostly depends on the quality of the included studies. However, the ability to detect FENO might vary among institutions in which those studies were performed and might cause bias of the reported NO levels. Considering this limitation, calculation using the random-effects model might be able to minimize this problem. Inhaled steroid treatment is another vital confounding factor of FENO measurement since inhaled corticosteroids decreased FENO levels and inhaled β~2~ agonists increased FENO levels.[@b46-copd-13-2695] However, not all participants included in this meta-analysis were free from such treatment. Limited by the data, we did not perform analyses assessing FENO levels in subjects free from inhaled steroid treatment. Additionally, the association between FENO levels and quality of life and pulmonary function were also unevaluable due to the amount of information available. It is necessary to acknowledge another limitation in our search strategy. We did not search the Chinese database. Several studies aiming at the association between COPD and FENO levels in Chinese might have been excluded from this study. Our funnel plot showed an obvious publication bias, which may result from clinical and methodological differences among studies. Another source of asymmetry may be from the studies where the sample size was small but the result showed a strong effect.

Future practice
===============

The usefulness of FENO measurement in clinical management of COPD still needs to be evaluated in a long term of practice and requires more high-quality studies. Importantly, the association between exacerbated COPD and FENO levels and the underlying mechanism in COPD exacerbation should be further investigated and explained. Since COPD is a neutrophilic airway inflammation, it is interesting that antioxidants and theophylline may have an effect on COPD since they may interfere with neutrophilic inflammation.

Conclusion
==========

Our findings indicated a mild elevation in FENO levels in patients with COPD compared with controls, as well as in patients with stable COPD. No association was observed in exacerbated COPD, which might result from the limited studies assessed. With regard to difference in smoking status in COPD, we concluded that ex-smokers had higher levels of FENO than current smokers.
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Sensitivity analysis of included studies by omitting each study.
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Funnel plot of exhaled nitric oxide in COPD.
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![Flow diagram of literature search and study selection.\
**Abbreviation:** COPD, chronic obstructive pulmonary disease.](copd-13-2695Fig1){#f1-copd-13-2695}

![Comparison of FENO levels between COPD patients and controls in the included studies.\
**Abbreviations:** CI, confidence interval; COPD, chronic obstructive pulmonary disease; FENO, fractional exhaled nitric oxide; IV, inverse variance; SMD, standard mean deviation; SD, standard deviation.](copd-13-2695Fig2){#f2-copd-13-2695}

![Comparison of fractional exhaled nitric oxide levels between stable/exacerbated COPD patients and controls.\
**Abbreviations:** CI, confidence interval; COPD, chronic obstructive pulmonary disease; FENO, fractional exhaled nitric oxide; IV, inverse variance; SMD, standard mean deviation; SD, standard deviation.](copd-13-2695Fig3){#f3-copd-13-2695}

![Comparison of FENO levels between ex-smokers and current smokers.\
**Abbreviations:** CI, confidence interval; FENO, fractional exhaled nitric oxide; IV, inverse variance; SMD, standard mean deviation; SD, standard deviation.](copd-13-2695Fig4){#f4-copd-13-2695}

###### 

Characters of included studies

  Study source                                   Study design   Study population             Gender (m/f)   Number of participants   COPD diagnosis     FENO measurement
  ---------------------------------------------- -------------- ---------------------------- -------------- ------------------------ ------------------ --------------------------------------------------------------------------------------------------------------------------------
  Kanazawa et al,[@b16-copd-13-2695] 1998        CS             Japan                        21/0           21                       ATS                Chemiluminescence analyzer (CLM-500; Shimazu; Kyoto, Japan)
  Rutgers et al,[@b23-copd-13-2695] 1998         CS             the Netherlands              25/7           32                       Doctor-diagnosis   Chemiluminescence analyzer (CLD 700 AL, ECO physics, Dürnten, Switzerland)
  Agusti et al,[@b29-copd-13-2695] 1999          CS             Spain                        27/0           27                       Doctor-diagnosis   Chemiluminescence analyzer (Dasibi Environmental, Glendale, CA, USA)
  Corradi et al,[@b28-copd-13-2695] 1999         CS             Italy                        32/18          50                       BTS                Chemiluminescence NO analyzer (model 42S; Thermo Environmental Instruments Inc, Franklin, MA, USA)
  Clini et al,[@b11-copd-13-2695] 2000           CS             Italy                        17/2           19                       ATS                Chemiluminescence analyzer (LR 2000 series; Logan Research; Kent, UK)
  Delen et al,[@b13-copd-13-2695] 2000           CS             America                      NA             77                       Doctor-diagnosis   Chemiluminescence (model 280; Sievers Instruments; Boulder, CO, USA)
  Papi et al,[@b20-copd-13-2695] 2000            CS             Italy                        24/5           29                       ERS                Chemiluminescence analyzer (NOA 280; Sievers)
  Montuschi et al,[@b19-copd-13-2695] 2001       CS             United Kingdom               27/25          52                       BTS                Chemiluminescence analyzer (model LR 2000; Logan Research; Rochester, UK)
  Hogman et al,[@b15-copd-13-2695] 2002          CS             Sweden                       NA             60                       Doctor-diagnosis   280 chemiluminescence analyzer (Sievers)
  Zietkowski et al,[@b27-copd-13-2695] 2005      CS             Poland                       58/29          87                       ERS                Chemiluminescence technique (Sievers 280i NO analyzer, Sievers)
  Brindicci et al,[@b10-copd-13-2695] 2005       CS             United Kingdom               27/24          51                       GOLD               Chemiluminescence analyzer (NIOXH; Aerocrine AB, Stockholm, Sweden)
  Ziora et al,[@b26-copd-13-2695] 2007           CS             Poland                       51/12          63                       GOLD               Chemiluminescent NO analyzer (model 280, Sievers Instruments)
  Liu et al,[@b17-copd-13-2695] 2007             CS             Australia                    NA             176                      Doctor-diagnosis   Chemiluminescent NO analyzer (Dasibi Environmental Corp.)
  de Laurentiis et al,[@b12-copd-13-2695] 2008   CS             Italy                        NA             69                       GOLD               Electrochemical FENO device (NIOX MINO, Aerocrine)/chemiluminescence analyzer (NOA, Sensormedics, Milano, Italy)
  Beg et al,[@b31-copd-13-2695] 2009             CS             Saudi Arabia                 39/0           39                       Doctor-diagnosis   Chemiluminescence analyzer (SERES, Aix-en-Provence, France)
  Lehouck et al,[@b33-copd-13-2695] 2010         CC             Belgium                      121/30         151                      GOLD               Chemiluminescence analyzer (NIOX, Flex; Aerocrine AB)
  Rouhos et al,[@b22-copd-13-2695] 2011          CS             Finland                      18/21          39                       Doctor-diagnosis   Chemiluminescence analyzer (Sievers 270B, Sievers)
  Maricic et al,[@b18-copd-13-2695] 2013         CS             Croatia                      NA             100                      GOLD               NA
  Sun et al,[@b25-copd-13-2695] 2013             CS             People's Republic of China   35/10          45                       CMA                The 4540-1999b portable nitric oxide gas detector (Interscan Corporation, Simi Valley, CA USA)
  Hirano et al,[@b14-copd-13-2695] 2013          CS             Japan                        24/12          36                       GOLD               Chemiluminescence-based NO analyzer NA-623N, (Chest Co. and Kimoto Electric Co., Tokyo, Japan)
  Moussa et al,[@b32-copd-13-2695] 2014          CC             Tunisia                      45/0           45                       Doctor-diagnosis   Electrochemical analyzer (Medisoft, Dinant, Belgium)
  Rawy and Mansour,[@b21-copd-13-2695] 2015      CS             Egypt                        61/29          90                       Doctor-diagnosis   Niox Mino analyzer (Aerocrine AG)
  Santini et al,[@b30-copd-13-2695] 2016         CS             Italy                        67/22          99                       GOLD               NIOX system (Aerocrine)
  Shrestha et al,[@b24-copd-13-2695] 2017        CS             Nepal                        91/121         212                      GOLD               Handheld Bedfont NO breath point-of-care device (Bedfont Scientific Ltd, Maidstone, Kent, UK, registered in England and Wales)

**Abbreviations:** ATS, American Thoracic Society criteria; BTS, British Thoracic Society guidelines; CC, case--control study; CMA, Chinese Medical Association guidelines; COPD, chronic obstructive pulmonary disease; CS, cross-sectional study; ERS, European Respiratory Society criteria; FENO, fractional exhaled nitric oxide; GOLD, Global Initiative for Obstructive Lung Disease; NA, not available.

###### 

Subgroup analyses

                                                      Studies (n)   Participants   SMD (95% CI)           *I*^2^ (%)
  --------------------------------------------------- ------------- -------------- ---------------------- ------------
  Total                                               24            1,669          1.28 (0.60--1.96)      96
  Subgroup                                                                                                
  COPD status                                                                                             
   Stable                                             20            1,393          1.21 (0.47--1.96)      96
   Exacerbated                                        2             53             3.20 (−3.22 to 9.61)   97
  Smoking status in COPD ex-smokers/current smokers                                                       
   COPD                                               7             323            2.05 (1.13--2.97)      90

**Abbreviations:** CI, confidence interval; COPD, chronic obstructive pulmonary disease; SMD, standard mean difference.
